Synlogic (SYBX)
OTHER OTC:SYBX
SYBX Stock Chart & Stats
$1.22
$0.02(1.41%)
At close: 4:00 PM EST
$1.22
$0.02(1.41%)
Day’s Range― - ―
52-Week Range$0.54 - $1.96
Previous CloseN/A
Volume234.00
Average Volume (3M)41.08K
Market Cap
$7.36M
Enterprise Value-$7.24M
Total Cash (Recent Filing)$14.67M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.41
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding11,698,919
10 Day Avg. Volume24,108
30 Day Avg. Volume41,078
Financial Highlights & Ratios
PEG Ratio0.14
Price to Book (P/B)1.16
Price to Sales (P/S)0.00
P/FCF Ratio-3.16
Enterprise Value/Market Cap-0.98
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda2.05
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Platform-based Engineered Microbial MedicinesA platform approach to program microbes for multiple metabolic and immunology indications provides structural optionality: successful science can be applied across programs, enabling pipeline diversification and potential licensing or partnership value that persists beyond short-term trials.
Sharply Reduced Cash Burn In 2025A pronounced reduction in operating cash burn signals meaningful cost control and lower near-term funding needs. Sustained lower burn improves runway credibility, reduces dilution pressure, and strengthens the company’s ability to advance clinical programs over a multi-month horizon.
Zero Debt / Low LeverageA net-zero debt position in recent annual periods materially lowers refinancing and interest-rate risk, giving management flexibility to fund operations through equity or partnerships. This durable conservatism improves solvency and reduces fixed-cost pressure over the next several quarters.
Bears Say
Shrinking Equity Base From Cumulative LossesA severe decline in equity reflects cumulative operating losses and weak capital retention, reducing the firm’s buffer against adverse outcomes. This erosion constrains financing options, increases dilution risk, and limits strategic flexibility over the coming quarters.
Minimal And Volatile RevenueEffectively no commercial revenue and high volatility meaningfully limit operating leverage and self-funding capacity. Over a multi-month horizon this forces dependence on external financing, making program continuity and R&D timelines contingent on capital availability.
Nasdaq Delisting And Move To OTCDelisting to OTC materially reduces market liquidity, institutional access, and public visibility, raising the long-term cost and difficulty of raising capital. For a cash-burning clinical-stage biotech, impaired access to markets increases execution risk for future trials and partnerships.
Synlogic News
SYBX FAQ
What was Synlogic’s price range in the past 12 months?
Synlogic lowest stock price was $0.54 and its highest was $1.96 in the past 12 months.
What is Synlogic’s market cap?
Synlogic’s market cap is $7.36M.
When is Synlogic’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Synlogic’s earnings last quarter?
Currently, no data Available
Is Synlogic overvalued?
According to Wall Street analysts Synlogic’s price is currently Overvalued.
Does Synlogic pay dividends?
Synlogic does not currently pay dividends.
What is Synlogic’s EPS estimate?
Synlogic’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Synlogic have?
Synlogic has 11,698,919 shares outstanding.
What happened to Synlogic’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Synlogic?
Currently, no hedge funds are holding shares in SYBX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Synlogic
Synlogic, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotic medicines to treat metabolic and immunological diseases in the United States. Its therapeutic programs include SYNB1618 and SYNB1934 that are orally administered, non-systemically absorbed drug candidates, which are in Phase II clinical trials to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate to treat homocystinuria; and SYNB8802, an orally administered, non-systemically absorbed drug candidate that is in Phase I clinical trial for the treatment of enteric hyperoxaluria. The company is also developing SYNB1891, an intratumorally administered synthetic biotic medicine that is in Phase I clinical trial to treat solid tumors and lymphoma. It has a collaboration agreement with F. Hoffmann-La Roche Ltd; Hoffmann-La Roche Inc.; and Ginkgo Bioworks, Inc. Synlogic, Inc. is headquartered in Cambridge, Massachusetts.
Technical Analysis
Lisata Therapeutics
―
Aptevo Therapeutics
―
SeaStar Medical Holding
―
Cingulate Inc
―
Allarity Therapeutics
―
Ownership Overview
0.37% Insiders
2.08% Mutual Funds
53.67% Other Institutional Investors
43.88% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---